{
  "source": "PA-Notification-Koselugo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1322-5\nProgram Prior Authorization/Notification\nMedication Koselugo™ (selumetinib)\nP&T Approval Date 8/2020, 8/2021, 8/2022, 9/2023, 9/2024\nEffective Date 12/1/2024\n1. Background:\nKoselugo is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and\nolder with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform\nneurofibromas (PN).\nThe National Comprehensive Cancer Network (NCCN) recommends Koselugo therapy in patients\nas a single-agent treatment for recurrent or progressive NF-1 mutated glioma, or recurrent or\nprogressive circumscribed glioma with BRAF fusion or BRAF V600E activating mutation. NCCN\nalso recommends Koselugo therapy in patients with Langerhans cell histiocytic neoplasms that are\nmitogen-activated protein (MAP) kinase pathway mutation positive or when there is no detectable\nmutation or testing available.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Koselugo will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Neurofibromatosis Type 1\n1. Initial Authorization\na. Koselugo will be approved based on both of the following:\n(1) Diagnosis of neurofibromatosis type 1\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Patient has plexiform neurofibromas that are both of the following:\n(a) Inoperable\n(b) Causing significant morbidity (e.g., disfigurement, mo",
    " type 1\n© 2024 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Patient has plexiform neurofibromas that are both of the following:\n(a) Inoperable\n(b) Causing significant morbidity (e.g., disfigurement, motor dysfunction, pain,\nairway dysfunction, visual impairment, bladder/bowel dysfunction)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Koselugo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Koselugo\ntherapy\nAuthorization will be issued for 12 months.\nC. Glioma\n1. Initial Authorization\na. Koselugo will be approved based on all of the following:\n(1) One of the following:\n(a) Circumscribed glioma with presence of BRAF fusion or BRAF V600E\nactivating mutations\n(b) NF-1 mutated glioma\n-AND-\n(2) Disease is recurrent or progressive\n-AND-\n(3) Used as monotherapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Koselugo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Koselugo\ntherapy\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nD. Langerhans Cell Histiocytosis\n1. Initial Authorization\na. Koselugo will be approved based on all of the following:\n(1) Diagnosis of Langerhans cell histiocytosis\n-AND-\n(2) One of the following:\n(a) Presence of MAP kinase pathway mutation\n(b) No detectable mutation\n(c) Genetic testing not available\n-AND-\n(3) Used as monotherapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Koselugo will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Koselugo\ntherapy\nAuthorization will be issued for 12 months.\nE. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued",
    "tment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n© 2024 UnitedHealthcare Services, Inc.\n3\n• Supply limits may be in place.\n4. References:\n1. Koselugo [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed July 30, 2024.\nProgram Prior Authorization/Notification – Koselugo™ (selumetinib)\nChange Control\n8/2020 New program.\n8/2021 Annual review. Added coverage criteria for pilocytic astrocytoma per\nNCCN guidelines. Updated background and references.\n8/2022 Annual review. Added coverage criteria for Langerhans cell\nhistiocytosis per NCCN guidelines. Updated background and\nreferences. Added state mandate footnote.\n9/2023 Annual review. Removed criteria for pilocytic astrocytoma. Added\ncriteria for glioma. Updated reference.\n9/2024 Annual review. No changes to clinical criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}